Mazdutide
Dual GLP-1/Glucagon receptor agonist developed in China showing 18%+ weight loss with additional metabolic benefits.
Last updated: August 2026
Category
Weight Loss (GLP-1/Glucagon)
Frequency
Once weekly injection
Research
Phase 3 Clinical TrialsWhat is Mazdutide?
Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor agonist developed by Innovent Biologics in China. [5] It shares the dual-agonist approach of retatrutide but without the GIP component, instead pairing GLP-1 with glucagon agonism, which drives thermogenesis and direct fat oxidation. Browse all weight loss peptide options to compare.
In Phase 3 clinical trials conducted primarily in Chinese and Asian populations, Mazdutide demonstrated approximately 18% body weight reduction over 36 weeks, positioning it between tirzepatide (22.5%) and semaglutide (15%) in terms of efficacy. Given that clinical trial populations were Asian, results may be particularly relevant to Vietnam users.
Mazdutide also shows promise beyond weight loss: trials have demonstrated improvements in NAFLD (fatty liver disease), with significant reductions in liver fat content. This makes it particularly interesting for users with metabolic liver conditions.
How It Works
GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, enhance insulin secretion, and slow gastric emptying, the same core mechanism as Semaglutide and the GLP-1 component of Tirzepatide. [6]
Glucagon Agonism: Activates glucagon receptors which directly increase metabolic rate (thermogenesis), stimulate fat oxidation particularly in the liver, and enhance energy expenditure. [7] This is the key differentiator from pure GLP-1 drugs.
Hepatic Fat Reduction: The glucagon component has particular efficacy in reducing liver fat (hepatic triglycerides), making Mazdutide uniquely effective for NAFLD/MAFLD alongside its weight loss properties. [8]
Benefits
- ~18% average body weight reduction in Phase 3 trials [9]
- Significant reduction in liver fat: useful for NAFLD
- Improved insulin sensitivity and HbA1c reduction
- Favorable Asian population trial data (directly relevant)
- Weekly dosing for convenience
- Thermogenic effect from glucagon agonism
- Emerging availability as research peptide in Vietnam
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Investigational (clinical trials) | No approved dose | Once weekly in trials (subcutaneous) | Not established |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Side Effects
Common
- ⚠Nausea (most common during titration)
- ⚠Decreased appetite
- ⚠Diarrhea
- ⚠Vomiting (resolves with slower titration)
- ⚠Injection site reactions
Rare
- •Elevated liver enzymes (monitor if pre-existing liver disease)
- •Hypoglycemia risk with concurrent diabetes medications
- •Gallbladder issues (associated with rapid weight loss)
- •Pancreatitis (rare, discontinue if severe abdominal pain)
Who Should NOT Use Mazdutide
- ✕Personal or family history of medullary thyroid carcinoma
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [10]
- ✕History of pancreatitis
- ✕Severe hepatic impairment
- ✕Pregnancy or breastfeeding
- ✕Under 18 years old
What to Expect
Starting dose phase. Appetite reduction begins. Nausea may occur but is typically manageable.
Appetite markedly reduced at titration dose. Weight loss accelerates, often 1 to 1.5kg per week with dietary awareness.
Consistent fat loss continues. The glucagon component produces noticeable thermogenic benefit: users often report feeling warmer and more energetic.
Notes from Ho Chi Minh City
Mazdutide is the GLP-1/glucagon dual agonist with the most relevant trial base for the Vietnam expat population specifically, because the Phase 3 program ran in Asian-population cohorts at Innovent Biologics' Beijing and Shanghai sites, closer to HCMC baseline body composition than the European-American Mounjaro and Wegovy trials. Those trials reported roughly 18 percent body-weight reduction at a 6mg weekly maintenance dose, and the glucagon-driven thermogenic effect is real enough that users describe feeling warmer for a day or two after dosing, notable in HCMC heat. The hepatic-fat reduction from the glucagon component is clinically interesting because NAFLD is widespread among middle-aged Vietnamese men. On the Vietnam market, Mazdutide is research-grade only and sourced through cold-chain importers. Dosing decisions belong with a licensed prescriber. [11]
Sourcing in Vietnam
Mazdutide is approved in China through Innovent Biologics but is not registered with the DAV in Vietnam and is not stocked at Long Châu, Pharmacity, FV Hospital, or Vinmec. The material that circulates in Vietnam is research-grade, brought in by cold-chain importers and often shipped by regional suppliers working from Chinese stock. See the supplier list and COA guide before purchasing.
FAQ
Q: Is Mazdutide available in Vietnam?
A: Mazdutide is less widely available than retatrutide or tirzepatide but is emerging in the research peptide market. Check the community-verified supplier list for current Vietnam availability and verify purity with the COA verification guide.
Q: How does Mazdutide compare to Tirzepatide?
A: Tirzepatide combines GLP-1 and GIP, while Mazdutide combines GLP-1 and Glucagon. Tirzepatide generally produces slightly more weight loss (22.5% vs 18%), but Mazdutide may have superior effects on liver fat. Both are weekly injections.
Q: Is Mazdutide FDA approved?
A: No, Mazdutide is developed by a Chinese company and has primarily been trialed in China. It is not FDA approved but is available as a research peptide. It shares the same receptor mechanisms as approved drugs (Ozempic, Mounjaro) so the safety profile is relatively well understood.
Where to Get Mazdutide in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Research & Sources
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight · Ji L, Jiang H, Bi Y, et al. · New England Journal of Medicine (2025) (PMID: 40421736)
Phase 3 GLORY-1 trial demonstrating approximately 18 percent weight reduction at 6mg weekly in Chinese adults with obesity.
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial · Zhang B, Cheng Z, Chen J, et al. · Diabetes Care (2024) (PMID: 37943529)
Phase 2 trial in type 2 diabetes supporting the dual GLP-1/glucagon agonism mechanism for glycemic and weight outcomes.
- IBI362, a long-acting GLP-1 and glucagon receptor dual agonist · Lu W, Chen J, Liu T, et al. · Frontiers in Pharmacology (2022) (PMID: 36034885)
Pharmacological characterization of mazdutide receptor binding and dual-agonist activity profile.
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease · Baggio LL, Drucker DJ · Molecular Metabolism (2021) (PMID: 32987188)
Mechanistic review of the rationale for combining glucagon agonism with GLP-1 for enhanced weight loss and hepatic fat reduction.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial · Ji L, et al. · EClinicalMedicine (2022) (PMID: 36247927)
- The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review · Liu Z, et al. · Drug design, development and therapy (2025) (PMID: 41312047)
- Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity? · Conceição-Furber E, et al. · Frontiers in endocrinology (2022) (PMID: 35547006)
- prnewswire.com / news releases innovent presents the key results of the first phase 3 (n.d.) Link
- innoventbio.com (n.d.) Link
- Multiple Endocrine Neoplasia Type 2 · Eng C, Plitt G (1993) (PMID: 20301434)
- The Rational Basis for Personalized Treatment Using Concentration-Guided Dosing · Holford N, Petric Z · Therapeutic drug monitoring (2025) (PMID: 40493392)
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.